Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection. What will really matter in the long run? That’s the question we tackle each year as ...
Gilead's HIV portfolio remains dominant but faces Medicare Part D pricing pressure, limiting future growth potential. New ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback